Identification of Cerebrospinal Fluid With Injeq IQ-Needle During

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is clinical feasibility study on the device performance with paediatric patients. The main objective is to validate the performance of investigational device in distinguishing and identifying the cerebrospinal fluid (CSF) inside the subarachnoid space during a lumbar puncture on paediatric patients.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05302765` - Intravenous Fluid Administration's Effect on Pediatric Lumbar Puncture	N/A

NCT number	NCT02792660
Study type	Interventional
Source	Injeq Ltd
Contact
Status	Completed
Phase	N/A
Start date	July 2016
Completion date	November 2018

Identification of Cerebrospinal Fluid With Injeq IQ-Needle During Paediatric Lumbar Puncture

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms